Apollomics Inc., a clinical-stage biopharmaceutical company, has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on April 1, 2024. The company, incorporated in the Cayman Islands and headquartered in the United States, is preparing for the sale of Class A ordinary shares and warrants. The registration statement includes a prospectus for the resale of shares by certain selling securityholders, although the company will not receive any proceeds from these sales. However, Apollomics will receive proceeds from any cash exercise of the warrants. The company's shares and warrants are listed on the Nasdaq under the symbols 'APLM' and 'APLMW' respectively. The financial statements for the year ended December 31, 2023, have been audited by Grant Thornton LLP and...Show More

Apollomics Inc., a clinical-stage biopharmaceutical company, has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on April 1, 2024. The company, incorporated in the Cayman Islands and headquartered in the United States, is preparing for the sale of Class A ordinary shares and warrants. The registration statement includes a prospectus for the resale of shares by certain selling securityholders, although the company will not receive any proceeds from these sales. However, Apollomics will receive proceeds from any cash exercise of the warrants. The company's shares and warrants are listed on the Nasdaq under the symbols 'APLM' and 'APLMW' respectively. The financial statements for the year ended December 31, 2023, have been audited by Grant Thornton LLP and Deloitte Touche Tohmatsu Certified Public Accountants LLP. Legal matters regarding the offering will be addressed by White & Case LLP and Conyers Dill & Pearman LLP. The company has also obtained a tax concession from the Cayman Islands government, ensuring no tax on profits, income, or capital gains for a period of twenty years from the date of the undertaking.